A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

NCT06171282 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteosarcoma
Sarcoma
Soft Tissue Sarcoma
Bone Tumor

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]